Patients on Rybelsus combined with sulphonylureas or insulin should be advised to carry glucose tablets or a fast-acting carbohydrate source at all times and ensure family members or colleagues know how to recognise and respond to hypoglycaemia
See individual product pages for full intended-use details
Wesseling-Perry 2009)
Flags theoretical pathologic angiogenesis potential: PMC12446177 Evidence Summary Preclinical: IBD/colitis models: High remission rates, restored mucosal architecture, improved barrier function Tendon repair: Accelerated healing, improved tensile strength, reduced fibrosis Neurovascular: Sciatic nerve protection, enhanced blood vessel growth in nerve tissue Human data (emerging): Interstitial cystitis pilot (2024, n=12): 10/12 complete resolution, 2/12 at 80% improvement IV safety study (2025, n=2): no adverse effects on cardiac, hepatic, renal, or glucose biomarkers Knee pain retrospective (2021, n=17): 91.6% reported significant improvement No large-scale controlled trials published Safety: No immunosuppression or hormonal disruption in available data 2025 systematic review (HSS Journal): recommends caution due to limited high-quality clinical evidence 2025 narrative review: flags theoretical pathologic angiogenesis risk Stable in gastric acid (oral administration viable) No observed toxicity at therapeutic doses in published reports Foundational Reviews Sikiric P, Seiwerth S, et al
Ligament repair: MCL-transected rats showed measurably greater ligament tensile strength and improved collagen alignment at 4 weeks (Chang et al., 2014)
